Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients. Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents naïve to corticosteroids (DMD). The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups. Affymetrix U133 Plus 2.0 expression microarrays were used to evaluate mRNA expression. Expression of 524 probes changed with corticosteroids, including genes in iron trafficking and the chondroitin sulfate biosynthesis pathway. Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism. These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.
Introduction
Duchenne muscular dystrophy (DMD) is caused by dystrophin gene mutations. 1 Lack of dystrophin causes muscle degeneration associated with chronic inflammation and fibrosis. 2 Randomized trials have demonstrated improved function and strength in DMD subjects treated with the corticosteroids prednisone (PRED) and the oxazoline derivative of prednisolone, Deflazacort (DEFL) (reviewed in Ref. 3 ). Fewer side effects, in particular less weight gain, are observed with DEFL. As azathioprine, another immunosuppressant, does not improve subjects with DMD, benefits from corticosteroid administration may or may not relate to immunosuppression. 4 Gene expression profiling of muscle has been used to classify muscular dystrophies and examine specific disease-related cell death and cell regeneration pathways in DMD. 5 Intravenous immunoglobulin treatment for inflammatory myopathy changes gene expression profiles in muscle, providing evidence for an alteration of the immune response with treatment in inflammatory muscle disease. 6 However, because understanding these mechanisms at the level of gene expression in muscle is limited by an invasive muscle biopsy, gene expression changes in blood could be used to monitor treatment and predict response. Earlier, we demonstrated that gene expression changes in peripheral blood can distinguish DMD patients from healthy controls. 7 In this report, we examined whether steroid administration in DMD patients would produce a specific profile of gene expression in blood when compared with steroid-naïve DMD patients. We also hypothesized that DEFL and PRED would generate distinct expression profiles that might indicate similar underlying mechanisms as well as side effect differences seen between these corticosteroids in DMD patients. This retrospective case-control whole genome expression microarray study demonstrates overall effects of corticosteroid treatment on mRNA expression in blood of DMD patients, and identifies expression profiles specific for DEFL and PRED within this cohort.
Results

DMD vs DMD-STEROID
mRNA expression changes in blood-total numbers of regulated genes. There was no difference in age between DMD-STEROID and DMD groups (unpaired t-test, P40.05, Supplementary Table S-1). Expression of 524 probes was significantly different in DMD compared with DMD-STEROID (fold changeX|1.5|, unpaired t-test, Pp0.05) (Figure 1a ; Supplementary Table S-2). Of these, expression levels were decreased in 127 probes (24%) and increased in 397 probes (76%) in DMD-STEROID compared with DMD (log-likelihood, Po0.00001) (Figure 1a ). Using these probes as input to prediction analysis of microarrays (PAM), 59 probes representing 50 annotated genes were identified that optimally distinguished DMD-STEROID from DMD. Ten-fold leave-one-out cross validation demonstrated that these probes correctly classify 29 of 34 subjects (85.2%) according to the drug use (Table 1; Figure 1b; Supplementary Table S-3) . All 20 subjects not using steroids (DMD) were correctly identified; 9 of 14 subjects (64.3%) using steroids (DMD-STEROID) were correctly identified. Of the subjects not correctly classified, three were being treated with PRED and two with DEFL (range of treatment: 2-108 months; age range: 4.5-14.4 years).
Promoter sites activated in blood of DMD-STEROID subjects. Using the list of 59 probes identified by PAM, transcription element listening system (TELiS) recognized 45 genes as present within its database. Using these genes, TELiS identified 13 transcription factor-binding motifs (TFBMs) that are significantly overrepresented within the 45 regulated genes, and one TFBM that is underrepresented within these probes (Supplementary Table S-4) . Glucocorticoid response elements do not appear within the identified TFBMs.
Biological significance assessment. Again using the list of 59 probes identified by PAM as input to The Database for (Figure 2a) . Conversely, 30 probes (6%) had significantly higher expression levels with DEFL compared with PRED (loglikelihood, Po0.00001) (Figure 2a ). Using these probes as input to PAM, 496 probes were capable of completely distinguishing DEFL from PRED. Ten-fold leave-one-out cross validation demonstrated that these probes correctly classify all subjects according to type of drug (Table 2 ; Figure 2b ; Supplementary Table S-7) . As the analysis comparing DEFL and PRED did not include the two subjects initially administered PRED and later converted to DEFL use, we examined whether the expression profiles for these subjects would resemble the DEFL or the PRED group. Using the 508-probe list, these two subjects show expression patterns similar to subjects on PRED using either unsupervised hierarchical clustering (Figure 3a ) or principal component analyses (Figure 3b ). Using the reduced list of 496 probes generated by PAM to predict group membership of these two subjects, PAM was able to correctly classify one of the two subjects (Supplementary 
Discussion
This study identified profiles of gene expression in whole blood resulting from corticosteroid treatment with DEFL and PRED in subjects with DMD. There are changes of gene expression common to both corticosteroids that may relate to the efficacy of both drugs in DMD. In addition, there are changes of gene expression that are specific for each drug that might relate to drug-specific side effects or therapeutic actions.
DMD-STEROID vs DMD
For the subjects using steroids (DMD-STEROID) compared with naïve DMD subjects (DMD), the DMD-STEROID group demonstrated enhanced defense responses and upregulation of genes associated with primary and secondary granules in granulocytes (neutrophils), iron trafficking, and chondroitin sulfate synthesis. The DMD-STEROID group had increased expression levels of lactotransferrin and lipocalin, genes involved in iron and heme homeostasis. Lactotransferrin, an iron-binding protein found in secondary granules of neutrophils, is important in the innate immune response against infections, and seems to be critically important in the oxidative burst during infections. 8 Our data confirm an earlier study that showed administration of corticosteroids to normal volunteers increased lactotransferrin protein levels in blood. 9 Lipocalin 2 is important in removing or preventing iron from entering siderophore bound iron in bacteria. 10 Lipocalin 2 also binds and carries iron in neutrophils, 11 and plays a role in resistance against tissue injury.
12 Both lactotransferrin and lipocalin 2 traffic iron to late endosomes in which acidification and reduction processes release iron stores. 13, 14 Steroids have earlier been reported to induce lipocalin both in vitro and in vivo. 15, 16 Expression levels of haptoglobin and CD163 were also upregulated in DMD-STEROID compared to DMD. Haptoglobin, made predominantly in the liver, binds hemoglobin and other heme proteins. It is specifically taken up by the receptor CD163 into macrophages, thus sequestering heme and the iron and preventing oxidative damage. 17 The upregulation of haptoglobin could serve to bind and sequester heme proteins released from injured or dying muscle fibers in DMD and other neuromuscular diseases. Corticosteroids induce haptoglobin protein production in blood of mammals and in cultured cells. 18, 19 Our data show that leukocytes increase expression of haptoglobin in response to corticosteroids in humans, confirming these earlier studies. Moreover, our findings are consistent with an earlier human study showing that corticosteroids also induced CD163 protein on the surface of peripheral blood monocytes. 20 It was suggested that corticosteroids facilitated CD163-mediated endocytosis of hemoglobin to monocytes/macrophages and thereby induced CD163 and heme oxygenase-1 (HO-1) synthesis. 20 As heme oxygenase-1 metabolizes heme from heme-containing proteins and helps sequester the iron that is released, this could account for some of the anti-inflammatory actions of corticosteroids. 21 Several corticosteroid-induced genes in our study, including lactotransferrin, cathepsin G, elastase, and azurocidin, directly bind ceruloplasmin, another iron-binding protein. 22 Ceruloplasmin, an endogenous antioxidant, oxidizes Fe 2 þ to Fe 3 þ , mitigating the oxidant effect of iron. 23 Though some of the above genes induced by corticosteroids have been reported earlier in other systems, this study demonstrates the coordinated induction of iron and heme regulatory genes in human leukocytes in response to corticosteroids. This is particularly interesting in light of therapeutic effects of iron deprivation demonstrated in the mdx mouse. 24 Genes in the chondroitin sulfate biosynthesis pathway are also upregulated in the DMD-STEROID patients. Biglycan and decorin, chondroitin/dermatan sulfate proteoglycans found in muscle extracellular matrix, have been shown to increase in DMD muscle. 25 They may act as regulators of fibrosis through inhibition of TGF-b1 profibrotic cytokine activity. 25 However, reduced sulphation of proteoglycans in and at the basal lamina has been identified in DMD muscle cell cultures. 26 Upregulation in our study of chondroitin b1,4 N-acetylgalactosaminyltransferase (ChGn, GALNACT-2) in response to corticosteroids might normalize proteoglycan sulphation and enhance antifibrotic effects of biglycan and decorin by contributing to initiation and elongation in biosynthesis of chondroitin sulfate.
Expression of FKBP5 is upregulated in the DMD-STEROID group. Upregulation of FKBP5 in response to corticosteroid use has been consistently demonstrated, including in the mdx mouse, 27 and has been associated with the loss of efficacy of corticosteroids.
27 FKBP5 protein inhibits calcineurin, 28 which controls and regulates slow-twitch oxidative (type I) muscle fibers. 29 Manual curation comparing expression changes in DMD-STEROID vs DMD to corticosteroid use in the mdx mouse 27 identified only one regulated probe in addition to FKBP5. KFL10, upregulated after 6 weeks of prednisolone administration in the mdx mouse, 27 was also upregulated in our DMD-STEROID group compared with the DMD group. KLF10 is a TGF-b inducible early gene that acts as a transcription factor regulator binding to GC rich Sp1-like sequences. 30 Thus, it is possible that although downstream expression changes differ between muscle and blood in response to steroid administration in DMD, these cascades are initiated by similar mechanisms.
Surprisingly, none of the probes whose expression was altered by corticosteroids in DMD patients had glucocorticoid (corticosteroid) response elements significantly overrepresented or underrepresented in TFBMs. However, the most significantly overrepresented TFBM family was the myocyte-specific enhancer factor-2 (MEF2) family (P ¼ 1.00E-10). The proteins in this family bind to the MEF2 DNA sequence in regulatory regions of most musclespecific genes. Other overrepresented transcription factor motifs included CEBPA (CCAAT enhancer-binding proteins), Figure 2 Probes separating Duchenne muscular dystrophy subjects on Deflazacort treatment (DEFL) compared with subjects on prednisone treatment (PRED). (a) Cluster analysis of genes (y axis) regulated in blood of subject groups (x axis): DMD-DEFL (left cluster) compared with DMD-PRED (right cluster). The 508 probes used for clustering were obtained by comparing DMD-DEFL to DMD-PRED (fold changeX|1.5|, unpaired t-test Pp0.05). (b) Prediction analysis of microarray (PAM) cross-validation probabilities: using 496 probes identified by PAM as best able to separate DMD-DEFL and DMD-PRED groups, ten-fold leave-one-out cross validation demonstrates the probability (y axis) of classifying subjects (x axis, subject IDs across the top) as DMD (pink) or DMD-STEROID (blue). All subjects (100%) are correctly classified.
Oct 6, and Brn 2. CEBPA are transcription factors involved in specification of myeloid lineages (i.e., all white blood cell types except lymphocytes) from stem cells and upregulation of expression for primary and secondary granule proteins. 31 The shift to a predominantly myeloid lineage immune response from lymphocyte defense responses in response to corticosteroids is further supported by underrepresentation of binding sites for Ikaros transcription factors, transcription factors regulating lymphocyte differentiation. 32 
DEFL vs PRED
In the DEFL group, expression of retinoic acid receptor a was significantly increased compared with PRED. Retinoic acid inhibits adipocyte differentiation through retinoic acid receptor a and increased expression of retinoic acid receptor a has been associated with reduced levels of obesity. 33, 34 Conversely, expression of a number of probes related to lipid metabolism, particularly, in adipose tissue was increased in PRED compared with DEFL. For example, CasBr-M (murine) ecotropic retroviral transforming sequence (CBL) is involved in adipose formation and energy homeostasis. 35 The nicotinic acid-coupled G protein-coupled receptor 109B (GPR109B) inhibits niacin-mediated lipolysis in adipose tissue, 36 as does G protein-coupled receptor 43, a short-chain fatty acid receptor. 37 Nuclear receptor coactivator 1, a coactivator required for transcriptional activity of the steroid receptor superfamily, is likewise involved in energy metabolism. 38 The interleukin 1 and interleukin 6 systems are both associated with obesity 39 and PRED was associated with increased expression of interleukin 1 b, interleukin 1 receptor antagonist and interleukin 6 receptor. Taken together, these findings suggest mechanisms by which weight gain, an important side effect of PRED, might be orchestrated, as well as a mechanism by which this side effect might be inhibited with DEFL.
Overall, there seem to be far fewer expression changes in the DEFL group compared with the PRED group. This may suggest that expression of the DEFL group is more similar to the untreated group than the PRED group. However, because response and side effects data were not collected for this preliminary study, it is not possible to state with any certainty whether these expression changes are related to lower occurrence of side effects of the DEFL treatment.
Limitations of this study include small sample size and statistical concerns surrounding multiple comparisons that would lead to false positives. In addition, it is important to note that expression differences might reflect effects or side effects of treatment, rather than a therapeutic effect. We are addressing these limitations in a new study with a novel cohort and targeted clinical data collection. Despite these limitations, our findings suggest corticosteroid administration fosters myeloid maturation, may suppress fibrosis, and seems to upregulate genes for primary and secondary granule proteins and subsequent iron trafficking functions in blood of subjects with DMD. Our findings further indicate pathways involved in weight gain and metabolism that are upregulated with PRED but not DEFL. Association of these pathways with corticosteroid administration points to mechanisms of corticosteroid actions in DMD that might provide specific treatment targets for other medications without side effects of corticosteroids.
Materials and methods
Study participants
Thirty-four subjects with DMD were enrolled in this study (mean age 9±3 years; 34 Caucasian, 3 Other) (Supplementary Table S-1). All subjects were seen at Cincinnati Children's Hospital Medical Center. Subjects were evaluated and diagnosed by a single board-certified pediatric neurologist (BW). Diagnoses were based on clinical history, examination findings, selected muscle biopsies, and molecular genetic tests. All DMD subjects had molecular genetic confirmation of the diagnosis.
DMD subjects on chronic steroids (n ¼ 14) (DMD-STEROID) were either being treated with PRED (n ¼ 6) or DEFL (n ¼ 8) at the time the blood samples were obtained (mean time on steroids 43.9 months, Supplementary Table S-1). Twenty DMD subjects had never been administered steroids.
For all subjects the parents provided informed consent and the children/adolescents provided either assent or consent. The study was approved by the Institutional Review Board at Cincinnati Children's Hospital Medical Center and was conducted in accordance with the Declaration of Helsinki.
Sample processing and array hybridization
For each participant, a total of 15 ml blood was collected into 6 PAXgene vacutainer tubes (PreAnalytiX, Germany) through antecubital fossa venipuncture. PAXgene tubes contain a proprietary reagent that immediately stabilizes RNA, thus reducing RNA degradation and minimizing changes of gene expression after phlebotomy. 40 After the blood draw the tubes were inverted 20 times, allowed to sit for 2 h at room temperature, and then stored flat at À70 1C until processed. 40 Total RNA was isolated using the Paxgene blood RNA kit (PreAnalytiX) according to the manufacturer's instructions. The RNA isolated comes from all cells in whole blood. Typical yields of total RNA isolated from the three Paxgene tubes of human whole blood (B7.5 ml) were between 10 and 40 mg. RNA quality and purity was analyzed by spectrophotometry using the Nanodrop ND-1000, and RNA integrity was analyzed using the Agilent 2100 Bioanalyzer. Samples achieved A 260 /A 280 absorbance ratios of purified RNA exceeding 2.0, and the 28S/18S rRNA ratios were equal to or exceeded 1.8.
Sample labeling, hybridization to chips, and image scanning were performed using standard Affymetrix protocols. For each whole blood sample, total RNA was labeled using the One-Cycle Target Labeling protocol and hybridized to the arrays. Gene expression was assessed on the Human U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA, USA), which consists of a single oligonucleotide microarray that surveys over 54 000 probesets. Doublestranded cDNA synthesis, biotin-labeled cRNA synthesis, and cRNA fragmentation were performed according to the Affymetrix GeneChip Eukaryotic Expression Analysis protocol. The labeled, fragmented cRNA (15 mg) was hybridized at 45 1C overnight. After hybridization, the array was washed and stained. The arrays were scanned with an argonion laser at l ¼ 570 nm, with a resolution of 3 mm/pixel (Affymetrix, Inc.).
Probe-level data analysis
After scanning the array, the raw expression values for each gene were saved in Affymetrix.cel files. For analyses comparing DMD and DMD-STEROID, the probe level data were imported into Genespring 7.2 (Agilent Technologies, Palo Alto, CA), and then processed using GC-RMA, followed by a three-step normalization (data transformation, per chip normalization, and per gene normalization) (Genespring 2004).
Statistical analyses
Statistical analyses, including t-test analyses, unsupervised hierarchical clustering, and principal component analyses were conducted using Genespring 7.2 software. Significance was assessed using the criteria at least 1.5-fold difference in expression between groups and statistically significantly different level of expression (parametric t-tests, Pp0.05). False discovery rates for identified probes are listed in the Supplementary Tables. To detect gene expression differences associated with steroid administration, between-group gene expression profiles for DMD compared with DMD-STEROID patients were generated using t-test analyses. The t-test analyses were also used to identify the expression profile distinguishing DEFL and PRED administration. Two subjects currently using DEFL that had earlier been on PRED (Supplementary Table S-1) were omitted from DEFL vs PRED t-test analyses. However, these subjects were included in subsequent clustering analyses to consider how earlier use of PRED affects later gene expression. Probe lists were analyzed using PAM 41 to identify the minimum number of probes/ genes that were able to differentiate specified groups.
Assessment of possible biological significance of identified genes
To examine co-regulation of gene pathways and biological significance, probe lists were imported into DAVID (http:// niaid.abcc.ncifcrf.gov/). 42 Using the Expression Analysis Systematic Explorer (EASE) program (EASE score), a modified Fisher Exact test score, DAVID identifies overrepresentation of gene lists within pathways, suggesting co-regulation of genes in a given pathway. DAVID default parameters were applied (minimum number of genes required per pathway or chromosome ¼ 2; maximum EASE score accepted ¼ 0.1). A DAVID Functional Annotation Clustering Report was used to identify similar annotations for identified probe lists. The Functional Annotation Clustering Report addresses redundancy of different annotation databases by grouping similar annotations together, and calculating a group enrichment score. The group enrichment score ranks these annotation groups (in -log scale of group members' P-values in each annotation cluster) according to degree of common genes identified across annotation databases. Therefore, higher group enrichment scores indicate increased level of biological significance (see http://david.abcc.ncifcrf.gov/ content.jsp?file ¼ functional_annotation.html). Additional literature review and manual curation were used to supplement DAVID findings.
As similar transcription factors might be involved in coordination of expression changes in response to corticosteroids, TFBMs overrepresented or underrepresented in differentially expressed probes were identified using the TELiS data base (http://www.telis.ucla.edu/). TELiS performs frequency analyses to compare the average number of TFBMs detected in promoters of differentially expressed genes with the average number in non-differentially expressed genes, using a z-test.
